Skip to main content
logo
Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
5.63
-0.08 (-1.32%)
Sep 2, 2026, 1:15 PM EDT - Market open

Revenue by Segment

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Developing AAV-Based Gene Therapies for The Treatment of Rare Monogenic Diseases
9.77M8.33M15.45M2.50M-
Total
9.77M8.33M15.45M2.50M-

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
United States
9.77M8.33M15.45M2.50M-
Total
9.77M8.33M15.45M2.50M-